Navidea and Massachusetts General Hospital to Evaluate Manocept™ for Detection of Cardiovascular Disease with NIH Grant
DUBLIN, Ohio, Navidea Biopharmaceuticals, Inc., is
announcing the receipt of a notice of award for a Phase 1 Small Business
Innovation Research (SBIR) grant providing $321K from the National Heart Lung
and Blood Institute (NHLBI), National Institutes of Health (NIH). The study, to
be done in collaboration with Massachusetts General Hospital (MGH) and Harvard
Medical School, will examine the ability of Tc 99m-tilmanocept, a Manocept™
platform product, to localize in high-risk atherosclerotic plaques. These
specific plaques are rich in CD206 expressing macrophages and are at high-risk
for near term rupture resulting in myocardial infarctions, sudden cardiac death
and strokes, accumulatively the leading cause of death in the US.
The consequences of atherosclerosis and the cardiovascular disease (CVD) that atherosclerosis causes, while severe in all populations of people, are particularly concentrated in HIV+ patients. “This Phase 1 pilot study may provide evidence that Tc99m-tilmanocept localizes in atherosclerotic plaques which would enable potential development of a diagnostic imaging agent that could benefit not only HIV+ patients but millions of people,” said Michael Tomblyn, M.D., Navidea’s Chief Medical Officer. “Positive outcomes would also support our Manocept development vision of a larger program that seeks to evaluate tilmanocept as a targeting vehicle to deliver therapies intended to limit or reverse atherosclerosis directly to plaques that could reduce cardiovascular disease (CVD) risk and improve outcomes for this patient population.”
“HIV infected patients suffer disproportionally from atherosclerosis and CVD,” commented Steven Grinspoon, M.D., Professor of Medicine at Harvard Medical School, Director MGH Program in Nutritional Metabolism, Co-Director of the Nutrition Obesity Research Center at Harvard and the study’s lead investigator. “There exists a profound and highly significant unmet need for means to better diagnose and treat atherosclerosis in all patients but particularly so in HIV patients. Manocept’s proven specificity for CD206 presents a clinically exploitable target with potential to achieve significant diagnostic and therapeutic results where few other approaches have progressed.”
About
the Phase 1 SBIR Clinical Study
Recently,
it has been observed that CD206 expressing macrophages densely populate
vulnerable plaques or thin cap fibroatheromas (TCFA) but not other kinds (i.e.,
stable) of atherosclerotic plaques. A primary goal for this grant involves an
approved clinical investigation of up to 18 individuals with and without aortic
and high risk coronary atherosclerotic plaques and with and without HIV
infection to determine the feasibility of 99mTc-tilmanocept to image high risk
plaque by SPECT/CT. Results have the potential to provide evidence of the
potential of 99mTc-tilmanocept to accumulate in high risk morphology plaques,
the ability to make preliminary comparisons of aortic 99mTc-tilmanocept uptake
by SPECT/CT in each group, and to evaluate the ability of 99mTc-tilmanocept to
identify the same aortic atherosclerotic plaques that are identified by
contrast enhanced coronary computed tomography angiography (CCTA) and/or PET/CT.
About
Atherosclerosis
Atherosclerosis is a chronic, progressive inflammatory condition resulting, over
the course of years or decades, in the formation of atherosclerotic plaques in
the walls of arteries. Atherosclerosis is the underlying pathology in the
majority of cases of cardiovascular disease (CVD) and a significant proportion of cases
of stroke. CVD and stroke are the first and fourth leading causes
of mortality in the US, respectively. Persons with advanced
atherosclerosis are frequently asymptomatic until one of their atherosclerotic
plaques ruptures, leading to blood clot formation, which restricts blood flow
to tissues. By this mechanism, rupture of atherosclerotic plaques causes
myocardial infarctions, sudden cardiac deaths and strokes.
About Lymphoseek
Lymphoseek® (technetium
Tc 99m tilmanocept) injection is the first and only FDA-approved
receptor-targeted lymphatic mapping agent. It is a novel, receptor-targeted,
small-molecule radiopharmaceutical used in the evaluation of lymphatic basins
that may have cancer involvement in patients. Lymphoseek is designed for the
precise identification of lymph nodes that drain from a primary tumor, which
have the highest probability of harboring cancer. Lymphoseek is approved by the
U.S. Food and Drug Administration (FDA) for use in solid tumor cancers where
lymphatic mapping is a component of surgical management and for guiding
sentinel lymph node biopsy in patients with clinically node negative breast
cancer, melanoma or squamous cell carcinoma of the oral cavity. Lymphoseek has
also received European approval in imaging and intraoperative detection of
sentinel lymph nodes in patients with melanoma, breast cancer or localized
squamous cell carcinoma of the oral cavity.
Accurate diagnostic evaluation of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. Overall in the U.S., solid tumor cancers may represent up to 1.2 million cases per year. The sentinel node label in the U.S. and Europe may address approximately 235,000 new cases of breast cancer, 76,000 new cases of melanoma and 45,000 new cases of head and neck/oral cancer in the U.S., and approximately 367,000 new cases of breast cancer, 83,000 new cases of melanoma and 55,000 new cases of head and neck/oral cancer diagnosed in Europe annually.
Source: Navidea
Comments